erlotinib has been researched along with nimodipine in 2 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (nimodipine) | Trials (nimodipine) | Recent Studies (post-2010) (nimodipine) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 2,936 | 317 | 597 |
| Protein | Taxonomy | erlotinib (IC50) | nimodipine (IC50) |
|---|---|---|---|
| Voltage-dependent L-type calcium channel subunit alpha-1C | Cavia porcellus (domestic guinea pig) | 0.11 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 2.19 | |
| Cannabinoid receptor 1 | Homo sapiens (human) | 1.736 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 4 | |
| Cytochrome P450 2J2 | Homo sapiens (human) | 3.38 | |
| Voltage-dependent calcium channel subunit alpha-2/delta-1 | Homo sapiens (human) | 0.0298 | |
| Voltage-dependent L-type calcium channel subunit beta-2 | Homo sapiens (human) | 0.0298 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Homo sapiens (human) | 7.15 | |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 0.0699 | |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C | Homo sapiens (human) | 1.243 | |
| Bile acid receptor | Homo sapiens (human) | 8.96 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
2 review(s) available for erlotinib and nimodipine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |